Craft

Flex Pharma

Stock Price

$0.6

2019-07-19

Market Capitalization

$11 M

2019-07-19

Revenue

$1.8 M

FY, 2021

Flex Pharma Summary

Company Summary

Overview
Flex Pharma is a biotechnology company that develops treatments for muscle cramps and spasms associated with severe neurological conditions and exercise-associated muscle cramps. The Company offers the product for the treatment of patients with multiple sclerosis. It also provides HOTSHOT, a consumer beverage to prevent and treat exercise-associated muscle cramps. The company merged with Salarius Pharmaceuticals, LLC to form Salarius Pharmaceuticals, Inc.
Type
Public
Status
Closed
Founded
2014
HQ
Boston, MA, US | view all locations
Website
http://www.flex-pharma.com/
Cybersecurity rating
Sectors

Key People

  • William McVicar

    William McVicar, President and Chief Executive Officer, Director

  • Peter Barton Hutt

    Peter Barton Hutt, Director

    • Marc Kozin

      Marc Kozin, Director

      • Stuart Randle

        Stuart Randle, Director

        LocationsView all

        1 location detected

        • Boston, MA HQ

          United States

          800 Boylston St

        Flex Pharma Financials

        Summary Financials

        Net income (Q3, 2022)
        ($14.4M)
        Cash (Q3, 2022)
        $16.8M
        EBIT (Q3, 2022)
        ($14.5M)

        Footer menu